Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict which heart blockages will worsen after stenting?

NCT ID NCT07748754

Knowledge-focused Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This observational study looks at why some untreated coronary artery blockages get worse over time in people who have already had a stent or balloon procedure for heart disease. Researchers will follow 1,400 adults aged 18-80 who are scheduled for a repeat angiogram, tracking their medical history, blood markers, and imaging to identify risk factors for lesion progression. The goal is to understand whether the initial treatment choice (stent vs. balloon) influences future blockages and heart events, which could help tailor follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which patients are at higher risk for new heart blockages after stenting, potentially guiding more personalized follow-up care.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all patients, and the 3-year follow-up may not capture long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2020

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This observational study will recruit patients with known coronary artery disease who are scheduled for repeat coronary angiography at Beijing Anzhen Hospital, Capital Medical University. Eligible participants are adults aged 18 to 80 years with full decision-making capacity, who have a prior angiographic diagnosis of coronary artery disease (defined as ≥ 50% diameter stenosis in at least one coronary artery) and are indicated for a follow-up coronary angiography procedure. All enrolled participants must provide written informed consent before study participation. Patients will be excluded from the study if they undergo coronary artery bypass grafting during the index hospitalization, have angiographic images of insufficient quality to perform quantitative coronary angiography (QCA) or Angio FFR analysis, or present with severe concomitant valvular heart disease, cardiomyopathy, or active infection.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria To be eligible for enrollment in this study, participants must meet all of the following criteria: Aged 18 to 80 years, regardless of gender, with full decision-making capacity; Previously diagnosed with coronary artery disease (coronary artery diameter stenosis ≥ 50%) by coronary angiography, and scheduled to undergo repeat coronary angiography; Able to provide written informed consent. Exclusion Criteria Participants will be excluded from the study if they meet any of the following criteria: Undergoing coronary artery bypass grafting (CABG) during the index hospitalization; Poor angiographic image quality (vessel overlap, inadequate opacification) that precludes quantitative coronary angiography (QCA) or Angio FFR analysis; Concomitant severe valvular heart disease, cardiomyopathy, or active infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease (CAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease (CAD)

Contacts and locations

Locations

  • BeijingAnzhen Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.